473
We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.
 two patients with chronic myelocytic leukemia: Subject; local cutaneous reactions at sites of injection: Effect; administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses: Treatment; chronic myelocytic leukemia: Treatment.Disorder; pegylated interferon alfa-2b: Treatment.Drug; different doses: Treatment.Dosage; weekly: Treatment.Freq; subcutaneous injections: Treatment.Route
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 two patients with chronic myelocytic leukemia: Subject; local cutaneous reactions at sites of injection: Effect; administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses: Treatment; chronic myelocytic leukemia: Treatment.Disorder; pegylated interferon alfa-2b: Treatment.Drug; different doses: Treatment.Dosage; weekly: Treatment.Freq; subcutaneous injections: Treatment.Route